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Varicella-zoster virus (VZV) is a human a-herpesvirus that causes varicella (chickenpox) at primary infection and may
reactivate as herpes zoster. VZV is a T-lymphotropic virus in vivo. To investigate the T-cell tropism of VZV, we constructed a
recombinant virus expressing green fluorescent protein (VZV-GFP) under the CMV IE promoter. Coculture of VZV-GFP-
infected fibroblasts with II-23 cells, a CD4-positive human T-cell hybridoma, resulted in transfer of virus to II-23 cells. II-23
cells are susceptible to VZV-GFP infection as demonstrated by expression of immediate/early (IE62), early (ORF4), and late
(gE) genes. Recovery of infectious virus was limited, with only 1 to 3 in 106 cells releasing infectious virus by plaque assay,
indicating that transfer of virus results in a limited productive infection. In vitro infection of II-23 cells will be useful for further
analysis of VZV tropism for T-lymphocytes. © 2000 Academic PressINTRODUCTION
Varicella-zoster virus (VZV) is a human a-herpesvirus
that causes varicella (chickenpox) as the primary infec-
tion in susceptible individuals and may reactivate as
herpes zoster (shingles) (Arvin, 1996). The a-herpesvirus
subfamily of human Herpesviridae also includes herpes
implex virus (HSV)-1 and HSV-2. While most a-herpes-
viruses infect a variety of cell types in culture and a wide
spectrum of species and tissue types in vivo, VZV infec-
tion is highly restrictive with regard to species and tissue
type, propagating most efficiently in human cells, includ-
ing most human diploid fibroblast cell lines (Arvin, 1996).
VZV has also been grown in guinea pig embryo and
monkey kidney cells, and less efficiently in EBV-trans-
formed B-cells and neuronal cell lines (Assouline et al.,
1990; Fioretti et al., 1973; Geder et al., 1965; Koropchak et
al., 1989).
Our experience with the SCID-hu mouse model of VZV
pathogenesis revealed that VZV possesses the ability to
infect and replicate in T-cells within fetal thymus/liver
(thy/liv) implants and is released by infected T-cells as
cell-free virus (Moffat et al., 1995). The lymphotropism of
VZV is a characteristic shared with human herpes virus 6
(HHV-6) and HHV-7, and is an essential component of
natural infection (Arvin, 1996; Secchiero et al., 1994).
Primary infection of VZV involves spread of infected pe-
ripheral blood mononuclear cells (PBMCs) to distant
sites before effective VZV specific immunity is induced
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278(Arvin, 1996). T-lymphocyte-mediated immune responses
act to eliminate virus-infected PBMCs and to restrict
virus replication to skin lesions. If the immune response
is inadequate, VZV has the potential to cause dissemi-
nated infection of the lungs, liver, central nervous sys-
tem, and other organs (Myers, 1979). VZV DNA has been
recovered in 11–24% of PBMCs taken within 24 h of
onset of the rash from healthy individuals with acute
varicella by using cell culture methods and in 67–74% of
samples tested by in situ hybridization or polymerase
chain reaction (Koropchak et al., 1989, 1991; Sawyer et
al., 1992). The PBMC subpopulations that harbor infec-
tious virus during the cell-associated viremic phase have
not been identified in the natural host because of the low
frequency of positive cells (Asano et al., 1985; Koropchak
et al., 1989; Mainka et al., 1998). VZV replicates in both
CD41 and CD81 T-lymphocytes in the SCID-hu thy/liv
model (Moffat et al., 1995).
The efficiency of infection of lymphocytes in vitro, us-
ing either PBMCs or umbilical cord mononuclear cells is
low (1–5%) and VZV-positive cells are difficult to identify
by specific phenotype and separate from the infected
fibroblast inoculum (Koropchak et al., 1989; Soong et al.,
1999). Despite extensive testing of CD41 Jurkat and
lymphoblastoid-derived T-cell lines maintained with var-
ious growth factors, VZV T-cell tropism was not observed
in vitro in our experience until the CD41 T-cell hybrid-
oma, II-23 cell line, was evaluated. The II-23 T-cell hy-
bridoma, which was constructed by fusion of lectin-acti-
vated peripheral blood lymphocytes and CEM.TET1, a
variant of the CEM lymphoblastoid cell line, was initially
characterized by Ware et al. (1986) as an inducible model
system for the production of growth inhibitory/cytolytic
and growth promoting lymphokines and cytotoxic T-cell
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virus have been identified using the II-23 cell line (Mauri
et al., 1998).
Herpesvirus recombinants expressing the green fluo-
rescent protein (GFP) from the bioluminescent jellyfish
Aequorea victoria have proved useful in the study of viral
entry, protein trafficking, and pathogenesis. Several stud-
ies have reported using GFP as a marker for viral entry or
fusion with herpesviral structural proteins to visualize
trafficking of virion components in live, infected cells
(Desai and Person, 1998; Elliott and O’Hare, 1999; Foster
et al., 1998). We constructed a recombinant VZV (Oka
strain) expressing green fluorescent protein (VZV-GFP)
under the CMV immediate/early (IE) promoter. Using
GFP expression as a marker for viral entry, we demon-
strated that cultured II-23 T-cells are susceptible to VZV
infection. This novel model of T-cell infection with VZV
should be useful for the systematic analysis of host cell
surface components that mediate T-cell infection as well
as other studies of VZV pathogenesis.
RESULTS
Generation of VZV-GFP
The VZV genome is a linear double-stranded DNA
molecule consisting of approximately 125,000 bp that,
when cloned in cosmid vectors and transfected into
susceptible cells, results in the generation of mature
infectious virions (Cohen and Seidel, 1993; Dumas et al.,
1981; Mallory et al., 1997). We used a cosmid system for
generation of recombinant VZV-expressing green fluo-
rescent protein. In this system, four overlapping frag-
ments of genomic DNA from the vaccine Oka strain of
VZV were ligated into SuperCos1 vectors (Stratagene, La
Jolla, CA); these cosmids were kindly provided by
FIG. 1. Design of VZV-GFP insertion cassette. Four overlapping fragm
pvSpe1EGFP@Avr (spanning VZV nucleotides 94208 to 124884) contai
region, and the SV40 poly A region. The cassette was ligated into a uGeorge Kemble (Aviron, Inc., Mountain View, CA). Thecosmid clone pvSpe211EGFP@Avr, consisting of a
1.6-kb EGFP (enhanced green fluorescent protein) cas-
sette containing the CMV IE promoter, the EGFP coding
region, and the SV40 poly A region amplified from the
vector pEGFP-C1 (Clontech Inc.), was ligated into a
unique AvrII site in cosmid pvSpe21 at VZV nucleotide
112853 (Fig. 1).
Transfection of VZV cosmids
Purified DNA from intact cosmids and
pvSpe211EGFP@Avr cosmid were cotransfected into
human melanoma cells (Mallory et al., 1997). Cytopathic
effect was evident 5 to 6 days after transfection. Green
fluorescence denoting GFP protein expression was as-
sociated with infectious foci. GFP expression was local-
ized to the cytoplasm of virally infected cells and could
be detected by fluorescence microscopy and FACS anal-
ysis early in infection. The resulting recombinant VZV-
expressing GFP (VZV-GFP) was transferred from mela-
noma cells into human embryonic lung fibroblast (HELF)
cells by inoculation of uninfected HELF cells. GFP ex-
pression in HELF cells was stable at low passage and
distributed evenly in the cytoplasm of infected cells.
Growth kinetics and viral titers of VZV-GFP were similar
to vaccine Oka in fibroblasts. In Fig. 2A, a VZV-GFP-
infected HELF cell monolayer exhibited typical early VZV
plaque morphology. GFP expression was observed in the
same plaque, limited to the area of the syncytia, and was
evenly distributed in the cytoplasm of rounded, virally
infected cells (Fig. 2B).
VZV-infection of II-23 cells
The strong association of progeny virions with the
infected cell results in low titers of cell-free VZV obtained
f genomic VZV DNA were cotransfected into melanoma cells. Cosmid
-kb EGFP cassette containing the CMV IE promoter, the EGFP coding
vrII site at VZV nucleotide 112853.ents oby conventional methods of virus preparation. We inoc-
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281VARICELLA-ZOSTER INFECTIONulated II-23 cells by coculture with a VZV-GFP-infected
HELF cell monolayer (Fig. 2C) at 2–31 cytopathic effect.
Using a 1:100 starting ratio of infected to uninfected
HELF cells as the cell-associated VZV-GFP inoculum,
maximal transfer of virus was achieved by Day 3 of
coculture, resulting in up to 30% of II-23 cells expressing
GFP (Table 1). At equivalent CPE, low density cultures
resulted in significantly increased viral transfer (30.8% at
105 cells/ml compared with 0.5% at 107 cells/ml). GFP
expression in II-23 cells was detected after 24 h in
coculture and peaked at Day 3 (Fig. 3). Coculture of II-23
cells beyond 3 days resulted in a significant degradation
of the integrity of the VZV-GFP HELF cell monolayer and
did not increase levels of viral entry. As expected, trans-
fer of virus to II-23 cells was not synchronous, resulting
in a range in the intensity of GFP expression (Fig. 2D).
Activation of II-23 cells with a combination of PMA (pro-
tein kinase C pathway) and ionomycin (ionophore effect)
may upregulate expression of certain herpesvirus entry
mediators (Mauri et al., 1998). Prior activation of II-23
cells with PMA 6 ionomycin did not increase suscepti-
bility of II-23 cells to VZV-GFP compared with that of
untreated controls.
To verify that GFP expression was the result of viral
entry and not endocytosis of soluble GFP or fusion with
VZV-GFP-infected HELF cells, II-23 cellular transcription
was inhibited with actinomycin D prior to coculture. II-23
cells incubated with 0.1 mg/ml actinomycin D expressed
significantly lower levels of GFP than untreated II-23
cells (3.2 compared with 8.0%) after 24 h of coculture.
The reduction in GFP expression following actinomycin
D treatment indicates that viral gene transcription is
required for GFP expression.
FIG. 2. Histological characterization of VZV-infected II-23 cells. (A)
(magnification, 2003). (B) GFP expression in a VZV-GFP plaque on a H
are susceptible to infection with VZV-GFP by coculture on VZV-infec
monolayer infected with VZV-GFP (magnification, 2003). (D) FACS-sor
2003). (E) Immunohistochemical staining of VZV protein in II-23 cells
TABLE 1
Efficiency of VZV-GFP transfer to II-23 cells
IL-23 cell
density
Inoculum ratio (VZV-GFP infected:uninfected
HELF cells)
1:1 1:10 1:100 1:1000
107/ml 8.3 6 3.3a 3.0 6 0.1 0.5 6 0.3 0.2 6 0.1
106/ml 8.7 6 1.4 10.1 6 1.1 21.8 6 2.1 10.1 6 1.4
105/ml 10.6 6 2.6 14.6 6 0.5 30.8 6 1.2 14.9 6 1.7
a Percentage CD4/CD45/GFP-positive cells 6 SE.lower left-hand panel inset 5 staining with nonimmune IgG (magnification
FACS-sorted II-23 cells, lower left-hand panel inset 5 negative control (magnVZV-infected II-23 cells are not productively infected
Plaque assay of VZV-infected II-23 showed recovery of
infectious virus from 1 to 3 in 106 II-23 cells. The low level
f infectious virus suggests that, while II-23 cells are
usceptible to viral entry and some gene expression, the
ost cell does not provide a suitable environment for
fficient replication. No infectious virions were recovered
hen VZV-infected II-23 cells were treated by sonic dis-
uption prior to titration.
haracterization of VZV-GFP infection of II-23 cells
Western blot analysis. Western blot analysis was per-
ormed to see if the limited productive infection resulted
um iodide (PI) stain of a VZV-GFP plaque on a HELF cell monolayer
ll monolayer, same plaque as (A) (magnification, 2003). (C) II-23 cells
LF cell monolayers, dual PI/GFP stain of II-23 cells on a HELF cell
-positive II-23 cells Day 3 postinfection with VZV-GFP (magnification,
with VZV-GFP using the IgG fraction of a high titer polyclonal serum,
FIG. 3. Flow cytometric analysis of VZV infection of II-23 cells.
VZV-GFP-infected II-23 cells were decanted from coculture with VZV-
GFP-infected HELF cells and labeled with mouse monoclonal anti-CD4-
phycoerythrin (PE) and anti-CD45-allophycocyanin (APC) for fluores-
cent-activated cell sorting. Top panel: .97% of cells stained were CD4
and CD45 positive; bottom panel: GFP expression in CD4/CD45 II-23
cells. Uninfected II-23 cells (no coculture, control) are represented by
the solid histogram. VZV-GFP-infected II-23 cells are represented by the
hatched histogram. In this representative sample, of the CD4/CD45
II-23 cells gated for FACS analysis, 16% are GFP positive.Propidi
ELF ce
ted HE
ted GFP
infected, 2003). (F) In situ hybridization showing VZV DNA integration in
ification, 4003).
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282 ZERBONI ET AL.from a block in the expression of immediate early, early,
or late genes. VZV-infected II-23 cells express abundant
VZV protein of a, b, and g subclasses. The immediate/
arly gene IE62, a major component of the viral tegu-
ent, was expressed in VZV-infected II-23 cells (Fig. 4A).
onoclonal antibody to IE62 recognizes several phos-
hoproteins in VZV-infected cells between 175 and 180
Da. ORF4, a 51-kDa protein with sequence homology to
SV-1 ICP27, is a putative early gene and was expressed
n VZV-infected II-23 cells (Fig. 4B). VZV proteins of the g
subclass were detected using the IgG fraction of a high-
titer polyclonal human serum, which recognizes predom-
inantly late viral glycoproteins and antibody to glycopro-
tein E, the most abundant VZV glycoprotein made in
virus-infected cells (Figs. 4C and 4D).
Immunohistochemical staining. The distribution of viral
protein expression and viral DNA in VZV-infected II-23
cells was evaluated by immunohistochemical staining
and in situ hybridization. Viral protein expression, while
present in only a fraction of cells expressing GFP, was
apparent in an even distribution on the surface of II-23
cells (Fig. 2E). GFP expression was more sensitive than
viral DNA for detecting infected cells (Fig. 2F). Controls
using nonimmune serum for immunohistochemical
stains and using the vector alone as a probe for in situ
FIG. 4. Western blot analysis of VZV protein expression in II-23 cell
VZV-GFP-infected HELF cells (lane 2), uninfected II-23 cells (lane 3), FA
CD41/CD451/GFP-positive II-23 cells (lane 5) using the following prim
of a high titer polyclonal serum (C), mAb to VZV glycoprotein E.ybridization were negative (Figs. 2E and 2F: inset, lowerleft). The polyclonal antibody used for immunohisto-
chemistry recognizes predominantly late glycoproteins.
DISCUSSION
The specific targeting of cells of the immune system is
a characteristic of herpesviruses, many of which infect
T-cells, B-cells, or monocytes during acute or persistent
infection. Using GFP expression by a VZV-GFP recombi-
nant as a marker for viral entry, we demonstrated that
II-23 cells are susceptible to infection with VZV. However,
little infectious virus was released from GFP-expressing
II-23 cells, suggesting that while II-23 cells are suscep-
tible to viral entry, the host cell does not provide a
suitable environment for productive infection. The ex-
treme cell-associated replication of VZV precludes a pre-
cise analysis of its replication kinetics using a cell-free
virus inoculum. By analogy with HSV, VZV is presumed to
follow the cascade of immediate/early (a), early (b), and
ate (g) gene transcription that characterizes HSV infec-
ion (Roizman, 1996). VZV proteins of a, b, and g sub-
lasses were expressed in II-23 cells. Expression of
nvelope glycoproteins on the cell surface was pre-
erved and GFP expression could be detected in culture
or several days postinfection.
ern blot for VZV protein expression in uninfected HELF cells (lane 1),
rted CD41/CD451/GFP-negative II-23 cells (lane 4), and FACS-sorted
bodies: a-IE62 gene product (A), a-ORF4 gene product (B), IgG fractions. West
CS-soA prior study of VZV T-cell tropism in our laboratory
283VARICELLA-ZOSTER INFECTIONshowed that VZV entered PHA-activated T-lymphocytes
but viral replication in vitro was impaired (Koropchak et
al., 1989). Soong et al. (1999) showed that 3–4% of cord
blood T-cells, many of which express activation markers,
were infected after coculture with VZV-infected fibro-
blasts. Productive infection follows virion entry only if
intracellular conditions permit viral uncoating, transport
to the nucleus, viral gene expression, replication, assem-
bly, and egress. Perera et al. (1992) demonstrated that
the ORF62 gene product, the immediate/early viral trans-
activator, was capable of upregulating the expression of
VZV proteins of a, b, and g subclasses in activated
T-lymphocytes, using an in vitro transient expression
assay (Perera et al., 1992). These experiments suggested
that T-cells possess the machinery required for viral
transactivation and expression of immediate/early, early,
and late gene products. VZV infection of II-23 cells, like
cord blood T-cells, was associated with synthesis of all
classes of viral proteins. While no mechanism has been
identified for the limited replication of VZV during T-cell
infection, VZV virions may enter most lymphocytes by a
pathway that does not support productive infection,
virion assembly, or egress is blocked (Koropchak et al.,
1989).
VZV spreads in cultured human diploid fibroblast
monolayers in a cell-to-cell fashion, mediated by enve-
lope glycoproteins that enable cells to fuse into
megapolykaryocytes and form syncytia (Arvin, 1996;
Grose, 1990). Similarly, polykaryocytes and syncytia that
form in VZV-infected monolayers and the giant cells that
form in VZV skin lesions are not observed when VZV
infects T-cells in thy/liv implants (Moffat et al., 1995).
Unlike infection of tissue culture monolayers, in which
infected cells fuse into multinucleated syncytia, histolog-
ical analysis of GFP-expressing II-23 cells did not reveal
polynucleated or fused cells, indicating a difference in
pathogenic effect of VZV on T-cells.
Glycoproteins and other viral genes can affect VZV
replication differentially in tissue culture cells and also
T-cells and skin tissue in the SCID-hu model (Moffat et
al., 1995). The glycoprotein C of VZV was an essential
virulence determinant for skin but not in T-cells in the
SCID-hu model (Moffat et al., 1998). The ORF47 protein
kinase of VZV, which is dispensable for growth in human
diploid fibroblasts in vitro, was demonstrated to be a
determinant of T-cell tropism using the SCID-hu thy/liv
model (Moffat et al., 1998). II-23 cells provide another tool
for the analysis of VZV gene products that mediate inter-
action with T-cells.
HSV-1 and -2 infect II-23 T-cells and dendritic cells by
attachment of HSV envelope glycoprotein D (gD) to the
cellular herpesvirus entry mediator HveA (Montgomery
et al., 1996; Salio, 1999). Since VZV does not possess a
homolog to HSV gD, it may employ means of viral entry
and egress not shared among other a-herpesvirus family
members. Activation of II-23 cells results in transientexpression of several TNF-related ligands on the cell
surface (Ware et al., 1992). However, activation with PMA
and ionomycin did not alter susceptibility of II-23 cells to
VZV infection, suggesting that proteins of this family are
not indicated in VZV entry. Nevertheless, our results
suggest that, while II-23 cells allow for VZV viral entry
and protein expression, levels of VZV gene expression
and DNA replication are not adequate for productive
infection. The abortive replication cycle of VZV in II-23
cells should permit studies of viral entry and gene ex-
pression in VZV-infected T-cells.
MATERIALS AND METHODS
Generation of Oka strain of VZV-expressing GFP
(VZV-GFP)
Four overlapping fragments of genomic DNA from the
Oka strain of VZV were ligated into SuperCos1 vectors
(Stratagene); these cosmids were kindly provided by
George Kemble (Aviron, Inc.). The deletion of an AvrII site
from the original cosmid vector at SuperCos1 nucleotide
3359 produced a unique AvrII site at VZV nucleotide
112853, in cosmid pvSpe21 (Fig. 1).
The cosmid clone pvSpe211EGFP@Avr was gener-
ated as follows: A 1.6-kb EGFP (enhanced green fluores-
cent protein) cassette containing the CMV IE promoter,
the EGFP coding region, and the SV40 poly A region was
amplified from the vector pEGFP-C1 (Clontech Inc.) using
PCR primers that annealed upstream of the CMV IE
promoter and downstream of the SV40 polyA signal. The
primers were designed so that they would introduce an
AvrII restriction enzyme site at each end of the cassette.
The PCR product was isolated and digested with AvrII.
The cosmid vector pvSpe21 was digested at the unique
AvrII site at nucleotide 112853, between ORF65 and 66.
The EGFP cassette was ligated into the AvrII-cut cosmid
vector and clones were isolated that contained the EGFP
cassette in both orientations.
Cosmid transfections were done as previously de-
scribed (Mallory et al., 1997). After transfection, the mel-
anoma cells were kept at 37°C for 3 to 4 days,
trypsinized, and transferred to a 75-cm2 flask; plaques
appeared 5 to 6 days after transfection. Green fluores-
cence denoting GFP protein expression was observed
by fluorescent microscopy and associated with infec-
tious foci.
Viral infection and culture conditions
VZV-GFP was transferred from melanoma cells into
human embryonic lung fibroblasts (HELF) by inoculation
of uninfected HELF cells. Low-passage viral stocks were
prepared and stored at 270°C in freezing media with
10% DMSO (Moffat et al., 1995). The II-23 cell line (D7
subclone) was maintained in RPMI medium 1640 plus
supplements and 10% fetal calf serum (FCS) (Ware et al.,
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284 ZERBONI ET AL.1986). Infection of II-23 cells is achieved by coculture of
T-cells at 105–106 cells/ml on a monolayer of VZV-GFP-
nfected HELF cells at 2–31 cytopathic effect (CPE) for
–3 days with daily media changes. At high CPE, the
nfected HELF cell monolayer has poor integrity, result-
ng in inefficient transfer of VZV. The loss of monolayer
ntegrity results in a decrease in II-23 to HELF cell con-
act and thus a decrease in viral transfer. At high target
ell density (107/ml), cell viability was poor as a result of
nutrient depletion.
To evaluate the susceptibility of activated II-23 cells to
VZV entry, II-23 cells were activated for 4 h at 37°C with
phorbol ester (100 ng/ml) or PMA (100 ng/ml) with iono-
mycin (1 mg/ml) prior to infection with VZV-GFP. To eval-
ate the ability of actinomycin D to abolish expression of
FP in II-23 cells, II-23 T-cell hybridomas were pre-
reated for 30 min with 0.1 mg/mL actinomycin D and then
rested at 37°C for 6 h to allow for protein synthesis from
preexisting mRNA. Cells were then infected with VZV-
GFP as previously described. FACS analysis was per-
formed, comparing the percentage of GFP-positive II-23
cells in actinomycin D-treated cells and controls.
FACS analysis and cell sorting
II-23 cells were removed from the VZV-GFP HELF cell
monolayer by gentle pipetting, washed with phosphate-
buffered saline (PBS), and counted. Cells were resus-
pended at a concentration of 107 cells/ml in PBS with 1%
CS. The cells were labeled with mouse monoclonal
nti-CD4-phycoerythrin (PE) and anti-CD45-allophyco-
yanin (APC) (both from Becton Dickinson, Mountain
iew, CA) for 20 min at 4°C. The cells were then analyzed
sing a FACS Calibur or sorted using a FACS Vantage
Becton Dickinson, San Jose, CA). Three-color analysis
ermitted FACS sorting of GFP-positive and GFP-nega-
ive II-23 cells from cell-associated inoculum and cell
ebris (Fig. 3).
nfectious foci assay
FACS-sorted GFP-positive II-23 cells T-cells at 107/ml
were serially titrated in 24-well dishes in triplicate, pre-
seeded with 1.5 3 105 African green monkey kidney
(Vero) cells. The dishes were incubated for 10 days at
37°C in 5% CO2 and then fixed with 10% formalin. Green
laques were counted using an inverted fluorescent mi-
roscope. The number of infectious foci per well were
alculated. Cell-free viral release was also evaluated by
ranswell assay. FACS-sorted GFP-positive cells were
ither (1) untreated, (2) sonicated for 10 s in tissue
ulture media, or (3) sonicated for 10 s in PSGC (85%
BS, 5% sucrose, 10% FCS, 0.1% Na-glutamate) media
nd laid onto a 3.0-mm-pore-size membrane over a Vero
ell monolayer. As a control, FACS-sorted GFP-negative
ells were treated in a similar manner. No infectious foci
ere counted above background levels.estern blot
An aliquot of 106 FACS-sorted GFP-positive II-23 cells,
FP-negative II-23 cells, uninfected II-23 cells, unin-
ected HELF, and VZV-infected HELF cell controls were
reated with detergent extract buffer containing protease
nhibitors, sonicated for 1 min, and subjected to three
reeze/thaw cycles. Following standard techniques, cell
ysates were separated by SDS–PAGE and transferred to
mmobilon-P PVDF membranes (Moffat et al., 1995). The
total amount of protein of each sample was equivalent,
as verified by amido black stain. VZV proteins were
detected with a high-titer polyclonal human immune se-
rum and a secondary goat anti-human IgG horseradish
peroxidase conjugate. Rabbit polyconal anti-IE62 and
anti-ORF4 antibodies and a mouse monoclonal antibody
to gE (kindly provided by Paul Kinchington and Charles
Grose) were also used. ECL (enhanced chemilumines-
cence) reagents were added (Amersham, Buckingham-
shire, UK).
Immunohistochemistry and in situ hybridization
FACS-sorted GFP-positive and -negative II-23 cells
were cytospun onto poly-L-lysine-coated slides (EM Sci-
nces, Ft. Washington, PA), fixed in 4% paraformaldehyde
or 30 min at room temperature, washed in PBS, and
ir-dried overnight. Immunohistochemistry and in situ
ybridization was done as described previously (Moffat
t al., 1995). The VZV probe consisted of a 12.9-kb bio-
inylated plasmid pVZV-C, that is a pBR322 vector carry-
ng the HindIII fragment C of VZV genomic DNA. A neg-
tive control probe consisting of pBR322 vector alone
as used at the same concentration.
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